This study is in progress, not accepting new patients

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

a study on Myasthenia Gravis

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Orange, California and other locations
Dates
study started
estimated completion

Description

Summary

The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.

Official Title

A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Keywords

Generalized Myasthenia Gravis Myasthenia Gravis Muscle Weakness zilucoplan (RA101495)

Eligibility

You can join if…

Open to people ages 18 years and up

  • Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan study

You CAN'T join if...

  • With the exception of a prior zilucoplan trial, participation in another concurrent clinical trial involving an experimental therapeutic intervention (participation in observational studies and/or registry studies is permitted)

Locations

  • Site 31: University of California Irvine
    Orange California 92868 United States
  • Site 004: USC - Keck School of Medicine
    Los Angeles California 90033 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ra Pharmaceuticals
ID
NCT04225871
Phase
Phase 3 Myasthenia Gravis Research Study
Study Type
Interventional
Participants
At least 200 people participating
Last Updated